271 related articles for article (PubMed ID: 11060694)
1. Adenosine deaminase deficiency as the first target disorder in gene therapy.
Onodera M; Sakiyama Y
Expert Opin Investig Drugs; 2000 Mar; 9(3):543-9. PubMed ID: 11060694
[TBL] [Abstract][Full Text] [Related]
2. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
Smogorzewska EM; Weinberg KI; Kohn DB
Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
[TBL] [Abstract][Full Text] [Related]
3. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
[TBL] [Abstract][Full Text] [Related]
4. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID.
Bordignon C; Mavilio F; Ferrari G; Servida P; Ugazio AG; Notarangelo LD; Gilboa E; Rossini S; O'Reilly RJ; Smith CA
Hum Gene Ther; 1993 Aug; 4(4):513-20. PubMed ID: 8399494
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials.
Onodera M; Nelson DM; Sakiyama Y; Candotti F; Blaese RM
Acta Haematol; 1999; 101(2):89-96. PubMed ID: 10202239
[TBL] [Abstract][Full Text] [Related]
6. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
[TBL] [Abstract][Full Text] [Related]
7. Retrovirus mediated gene transfer as therapy for adenosine deaminase (ADA) deficiency.
Ramsey WJ; Mullen CA; Blaese RM
Leukemia; 1995 Oct; 9 Suppl 1():S70. PubMed ID: 7475319
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID.
Aiuti A; Brigida I; Ferrua F; Cappelli B; Chiesa R; Marktel S; Roncarolo MG
Immunol Res; 2009; 44(1-3):150-9. PubMed ID: 19224139
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy for adenosine deaminase deficiency.
Aiuti A; Ficara F; Cattaneo F; Bordignon C; Roncarolo MG
Curr Opin Allergy Clin Immunol; 2003 Dec; 3(6):461-6. PubMed ID: 14612670
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow transplantation and alternatives for adenosine deaminase deficiency.
Gaspar HB
Immunol Allergy Clin North Am; 2010 May; 30(2):221-36. PubMed ID: 20493398
[TBL] [Abstract][Full Text] [Related]
11. ADA Deficiency: Evaluation of the Clinical and Laboratory Features and the Outcome.
Cagdas D; Gur Cetinkaya P; Karaatmaca B; Esenboga S; Tan C; Yılmaz T; Gümüş E; Barış S; Kuşkonmaz B; Ozgur TT; Bali P; Santisteban I; Orhan D; Yüce A; Cetinkaya D; Boztug K; Hershfield M; Sanal O; Tezcan İ
J Clin Immunol; 2018 May; 38(4):484-493. PubMed ID: 29744787
[TBL] [Abstract][Full Text] [Related]
12. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency.
Onodera M; Ariga T; Kawamura N; Kobayashi I; Ohtsu M; Yamada M; Tame A; Furuta H; Okano M; Matsumoto S; Kotani H; McGarrity GJ; Blaese RM; Sakiyama Y
Blood; 1998 Jan; 91(1):30-6. PubMed ID: 9414266
[TBL] [Abstract][Full Text] [Related]
13. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.
Ferrua F; Aiuti A
Hum Gene Ther; 2017 Nov; 28(11):972-981. PubMed ID: 28847159
[TBL] [Abstract][Full Text] [Related]
14. Drug evaluation: ADA-transduced hematopoietic stem cell therapy for ADA-SCID.
Taupin P
IDrugs; 2006 Jun; 9(6):423-30. PubMed ID: 16752313
[TBL] [Abstract][Full Text] [Related]
15. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies.
Silver JN; Flotte TR
Pharmacogenomics; 2008 Jul; 9(7):947-68. PubMed ID: 18597656
[TBL] [Abstract][Full Text] [Related]
16. Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency.
Silver JN; Elder M; Conlon T; Cruz P; Wright AJ; Srivastava A; Flotte TR
Hum Gene Ther; 2011 Aug; 22(8):935-49. PubMed ID: 21142972
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy for ADA-SCID, the first marketing approval of an
Aiuti A; Roncarolo MG; Naldini L
EMBO Mol Med; 2017 Jun; 9(6):737-740. PubMed ID: 28396566
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency.
Montiel-Equihua CA; Thrasher AJ; Gaspar HB
Curr Gene Ther; 2012 Feb; 12(1):57-65. PubMed ID: 22348551
[TBL] [Abstract][Full Text] [Related]
19. Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID): Molecular Pathogenesis and Clinical Manifestations.
Bradford KL; Moretti FA; Carbonaro-Sarracino DA; Gaspar HB; Kohn DB
J Clin Immunol; 2017 Oct; 37(7):626-637. PubMed ID: 28842866
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients.
Bordignon C; Notarangelo LD; Nobili N; Ferrari G; Casorati G; Panina P; Mazzolari E; Maggioni D; Rossi C; Servida P; Ugazio AG; Mavilio F
Science; 1995 Oct; 270(5235):470-5. PubMed ID: 7570000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
